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Summary
Purpose: Status epilepticus (SE) is a major neurological condition associated with
significant morbidity and mortality. No studies to evaluate the cost burden of SE have
been performed to date. This study estimates the direct cost related to an inpatient
admission for SE in an urban academic medical center.
Methods: Cases of SE were defined based on a standard 30 min or greater seizure
duration. The inpatient claims data were analyzed for 192 patients admitted with SE
from 1 July 1993 through 30 June 1994. Patient demographic and clinical character-
istics associated with increased cost were identified using multiple regression. The
direct costs for SE were compared with other common DRGs.
Results: The median reimbursement for a patient with SE was $8417. The average
length of stay for all SE patients was 12.9 days. Age groups (17—45 and 46—64) and
etiology (acute CNS) were the only patient factors significantly associated with
increased cost. SE patients had 30—60% higher reimbursements than patients
admitted for other acute health problems including acute myocardial infarction or
congestive heart failure.
Conclusions: The direct inpatient costs for SE are high compared with the direct costs
of admissions for other major conditions such as acute myocardial infarction or
congestive heart failure. Data from this study were used to estimate a $4 billion
annual direct cost for inpatient admissions for SE. Given the incidence and the high
costs, further more detailed evaluation of these costs may be useful in assessing the
adequacy of reimbursement for this subset of patients with epilepsy.
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Studies assessing the cost-of—illness of various neu-
rologic diseases including epilepsy, refractory epi-
lepsy, and stroke have demonstrated a high
economic burden of these diseases on the health
care system, the patient and their families.1—8
Because this is a heterogeneous disease, the range
in the costs of epilepsy varied widely, depending on
the method and focus of the analysis, whether
direct and indirect costs were included, or whether
the disease is new onset or established.2,9 The
economic burden of epilepsy is high, with the great-
est cost per person occurring in the first year of
diagnosis and ranging from $917—3157. The costs in
subsequent years have been estimated to be lower,
ranging from $245—641.4,8 Status epilepticus (SE)
represents an important subset of the epilepsy
population because it is a major neurological and
medical condition associated with significant mor-
bidity and mortality.10—15 Estimating the costs attri-
butable to this entity independent of other epilepsy
disorders may be important not only because of the
severity of this disease, but also because of the
substantial number of cases. Epidemiologic data
from the Richmond, Virginia metropolitan area
determined that the annual incidence of SE was
41 episodes/100,000 adults per year in the United
States. This would result in approximately 200,000
cases occurring each year.10 SE may also occur in
association with other diseases such as metabolic
coma, or may be associated with neurologic condi-
tions such as stroke, tumor or hypoxic brain injury,
further complicating the measurement of the eco-
nomic burden of this disease.12 Given the high
incidence and the associated morbidity and mortal-
ity of SE 10—12,16,17 the economic burden of this
disease is likely to be significant. To date, there
have been no studies that have estimated the costs
related exclusively to status epilepticus.
Methods used to estimate the economic burden
of epilepsy have varied because of differences in
the inclusion of different components of health care
costs such as the direct medical costs to the health
care system or to the patient.4,6,7 Indirect costs are
an important contributor to the costs of epilepsy,
due to ongoing treatments and visits to the health
care provider.4,6—8 The majority of publications
that have assessed the costs of epilepsy have used
an annual cost estimate because it is difficult to
define an episode of care for epilepsy.2,5,8,9 Unlike
other forms of epilepsy, SE may lend itself better to
identifying an episode of care related to a hospital
admission. That admission is likely to represent the
largest proportion of direct costs to the health care
system. Given that the incidence burden of diseaseis substantial, and that the SE events are most likely
to occur in a high health care cost setting, studies to
estimate the cost of SE independent of that for
other seizures seems warranted.
Data from the NIH Greater Metropolitan Area
Status Epilepticus Data System provided a unique
opportunity to assess the economic burden to the
health care system associated with an inpatient
hospital admission for SE. Because the patients
were identified prospectively and comorbidity
information was collected the effect of other diag-
noses on the direct costs surrounding an episode of
SE could be examined. Finally, costs measured by
reimbursement and associated with an SE admis-
sion, were compared with those for other acute
admissions including myocardial infarction, stroke,
and congestive heart failure.Methods
Case definition
SE has been defined for all studies related to this
project using well-established criteria as (1) any
seizure lasting 30 min or longer; or (2) intermittent
seizures totaling more than 30 min, between which
the patient did not regain consciousness.10,11,13,15,18
Population
The Medical College of Virginia of Virginia (MCV)
Commonwealth University prospectively collects
and maintains epidemiologic and clinical data on
SE in the Greater Richmond Metropolitan Area Sta-
tus Epilepticus Data System.10,14 Data on a subset of
these patients, cases diagnosed and treated at MCV
Hospital, were used to assess the direct medical
costs as represented by reimbursement for inpati-
ent stays for SE. The inpatient claims data for 192
patients admitted to the MCV Hospital from 1 July
1993 through 30 June 1994 were analyzed to calcu-
late the direct economic burden of an episode of SE.
Patients admitted with an admission DRG of acute
myocardial infarction, cerebrovascular hemorrhage,
or congestive heart failure in 1994 were identified and
claims data were used to estimate the direct costs of
inpatient medical care for these diseases. The direct
costs measured as reimbursement provided a set of
relative comparisons for the same costs associated
with an admission for SE.
Costs
Because SE is treated primarily in the acute inpa-
tient setting, the largest proportion of the costs of
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inpatient admission in which the SE is diagnosed and
treated. We did not attempt to capture indirect
costs to the health care system, or other indirect
costs such as those incurred by the patient or family
for treatment of their condition. The purpose of this
study was to obtain a measure of the economic
burden of SE to the health care system, and to
compare that with the burden for other disease
entities. This was based on the reimbursement to
our health care system for a hospital admission for
SE. The relative costs for an SE admission versus
those for admissions for three other major diseases
were compared. The comparison was based on the
ratio of the reimbursement for admissions to our
institution. These results are presented as the ratios
of the average reimbursement amount for an inpa-
tient stay for SE divided by those for a specific
diagnosis (acute myocardial infarction, congestive
heart failure or cerebrovascular hemorrhage). This
ratio provides a relative measure of the direct health
care costs of SE that controls for the potential
variation in reimbursement rates across institutions.
Analysis
Patients were categorized for analysis into four age
groups: 0—16, 17—45, 46—64 and 65 and older. They
were also categorized by gender and by a dichot-
omous race variable (white/black). Etiologies were
grouped into five general categories as defined
previously: hypoxia (anoxic and hypoxic insults),
central nervous system (CNS) acute etiologies
(stroke, tumors, trauma and CNS infections),
nonCNS acute (metabolic disorders, systemic infec-
tions, and drug overdose), withdrawal (alcohol and
anti-epileptic drug withdrawal and undermedica-
tion for seizures) and cases related to a remote
or congenital origins (resolved stroke, birth injury,
or congenital anomaly).10,17,19,20
Other conditions that were included in the com-
parison of SE to other inpatient stay reimburse-
ments were selected based on Diagnosis Related
Groups (DRG) and International Classification of
Diseases 9th Edition (ICD-9) principle diagnosis.
For intracranial hemorrhage, cases with DRG 014
and a principle diagnosis of 431, 434.91 were
selected. For CHF, cases with DRG 122 or 124,
associated with a principle diagnosis of 428 were
selected. Acute myocardial infarction cases
included those with DRG 121, or 122 and a principle
diagnoses of 410. Inpatient stays for seizure (which
included primarily status stays) had DRGs 024 and
025 with a principle diagnoses 345 or 780.3.
The Statistical Analysis System (SAS) Univariate
procedure was used to calculate the mean, medianand interquartile ranges for reimbursement. The
interquartile range is the estimate between the
25th and 75th percentile. Nonparametric proce-
dures from the SAS Npar1way Procedure, including
the Median test and the Wilcoxin Rank sum
test were performed to assess differences in reim-
bursement across age, race, sex, and etiologic
groupings. For the univariate comparisons, median
costs were used to reduce the impact of a skewed
distribution.
Reimbursement amounts were calculated based
on the natural logarithm of the dollar amount. Using
the natural log to perform statistical calculations
and then transforming back to dollars reduces the
effect of skewedness of any cost data, and provides
a normalized distribution required for linear regres-
sion modeling. The SAS General Linear Models pro-
cedure was used to perform multiple linear
regression to identify factors significantly and inde-
pendently associated with increasing cost among SE
patients. Length of stay (LOS) was based on the total
number of days for each inpatient stay.
The relative direct cost burden of SE was com-
pared with that for other diagnoses during an acute
inpatient admission. The ratio of the average inpa-
tient reimbursement for SE was divided by the
average reimbursement amount for other specific
conditions including intracranial hemorrhage, con-
gestive heart failure (CHF), and acute myocardial
infarction (AMI).Results
A description and frequency distribution of the
study population by age group, race, sex, and SE
etiology are presented in Table 1. The estimates of
the median and interquartile range in reimburse-
ment for each of the demographic and etiologic
groupings for inpatient stays related to SE are pre-
sented in Table 2. Reimbursement differed signifi-
cantly across age groups and across etiologies in this
univariate comparison. There were no significant
differences by race or gender. Of 192 patients
included in this cohort and admitted with a diag-
nosis of SE in 1993—1994, the median inpatient
reimbursement was $8,417 with an interquartile
range of $5592—$21,155. The average length of
an inpatient stay for these cases was 12.9 days with
an interquartile range of 3—15 days. The median
direct cost as reflected by reimbursement and aver-
age length of stay for an inpatient hospital stay was
$1458 per day.
There was a nearly three-fold significant differ-
ence in the range of cost estimates based on reim-
bursement by age group (P = 0.002). The lowest
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Table 1 Status epilepticus (SE) Populationa.
Nb (%)c
Total population 192
Age group
0—16 70 (36)
17—45 46 (24)
46—64 38 (20)
65+ 38 (20)
Race
Black 62 (32)
White 130 (78)
Sex
Male 113 (59)
Female 79 (41)
Etiology
CNS Acute 43 (22)
Hypoxia 21 (11)
NonCNS acute 49 (26)
Remote/congenital 57 (30)
Withdrawal 22 (11)
Description: demographics and SE etiology.
a The SE population in this study consisted of all admission
for, SE to a large, urban academic hospital between 1 July
1993—30 June 1994.
b N: the number of patients with that characteristic in the
study population.
Table 3 Multiple logistic regression results predicting
increased cost associated with inpatient stays for sta-
tus epilepticus (SE).
Patient characteristic Cost multiplierb P-value
Intercept (baseline cost)a 6483.40 0.0001
Female 1.14 0.36
Black race 0.98 0.88
Age 17—45c 1.95 0.0006
Age 46—64c 1.74 0.008
Age 65+c 1.32 0.2
Hypoxiad 1.56 0.095
CNS acuted 2.23 0.0004
Remote/congenitald 0.89 0.53
Withdrawald 1.03 0.91
a Charges for a white, male SE patient, age 0—16 with
nonCNS acute etiology;.the SE patient with the lowest inpa-
tient cost.
b Factor by which baseline cost is multiplied for that
patient characteristic. For example: SE patients aged 25 have
1.95 times the cost of SE patients aged 0—16 years
($12,642.63).
c ‘‘0—16’’ age group is the comparison group for each of
the other 3 age groups. The cost for SE patients aged 65+ is not
significantly different than for SE patients aged 0—16 years.
d NonCNS acute is the comparison group for each of the
four other etiologies.were in the pediatric age group (0—16 years) and the
highest in the adult age group (17—45 years) as
shown in Table 2. A significant, 2.5-fold variation
was observed in reimbursement for SE according toTable 2 Direct costs (reimbursement) for an inpatient ad
characteristics and etiology.
Patient characteristics Reimbursementa
Median
Total $8,417
Age groupb
0—16 $6,140
17—45 $14,689
46—64 $9,520
65+ $8,938
Racec
Black $8,601
White $8,039
Sexc
Male $8,135
Female $8,234
Etiologyb
CNS Acute $16,919
Hypoxia $9,738
NonCNS acute $6,669
Remote/congenital $7,090
Withdrawal $11,239
a Reimbursement dollars are based on hospital inpatient claims
b There are statistically significant differences in reimbursemen
c There are no statistical differences in reimbursement by raceetiology (P = 0.0008). The highest were for the acute
CNS category and the lowest in the nonCNS Acute
category. Patients with an etiology of withdrawal
from alcohol or anti-epileptic drugs had the secondmission for status epilepticus by patient demographic
25th percentile 75th percentile
$5,592 $21,155
$3,423 $14,795
$7,892 $26,604
$5,449 $22,731
$7,514 $18,870
$5,449 $32,735
$5,419 $19,504
$5,492 $21,260
$5,410 $21,313
$8,092 $39,620
$8,037 $23,747
$3,823 $14,021
$4,328 $13,992
$6,136 $20,360
for 1993 and 1994.
ts across age groups (P = 0.002) and etiology (P < 0.001).
(P = 0.75) or gender (P = 0.9).
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Table 4 Comparison of the ratio of reimbursement for status epilepticus inpatient stays with other common
diagnoses.
Admission diagnosis Number of
admissionsa
Average
LOS
Average reimbursement
per admissionb
Reimbursement ratio
of SE/other Dx
Acute myocardial infarction 81 7.26 $10,393.14 1.81
Congestive heart failure 82 7.48 $9,684.72 1.94
Intracranial hemorrhage 62 9.30 $11,547.71 1.63
Status epilepticus 192 12.92 $18,834.88 1.00
a Inpatient admissions to an urban academic medical center between 1 July 1993—30 June 1994 one with a principle diagnosis and
DRG code listed in column.
b Average reimbursement = total average amount paid to the hospital for inpatient services provided for each of the diagnoses in
column one (across all payors).highest compared with other etiologies. There were
no significant differences by gender or race.
The results of the multivariate analysis are pro-
vided in Table 3. Neither race nor gender was
associated with higher costs for inpatient admis-
sions for SE as reflected by reimbursement. As in the
univariate analysis, age and etiology were signifi-
cant independent predictors of increasing reimbur-
sement. The lowest direct costs in the univariate
analysis were found for the pediatric age group (0—
16 years). Therefore, this group served as the refer-
ence group for the multiple regression. Admissions
for SE patients aged 17—45 and 46—64 had signifi-
cantly increased costs over the pediatric age group,
a nearly two-fold increase for those age 17—46, and
a 1.74-fold increase for persons aged 46—64. How-
ever, reimbursement for inpatient admissions for
those in the oldest age group (65+) were not sig-
nificantly higher than for the pediatric age group,
even after adjusting for etiology. SE resulting from a
CNS acute etiology had significantly higher costs
than were seen for persons in any other etiologic
category, including the reference group (nonCNS
acute).
Length of stay varied markedly in patients with
SE. Slightly over half the patients, 104 of 192 (54%)
had a LOS of less than one week (data not shown).
The reimbursement for patients increased corre-
sponding to an increased LOS. The average reim-
bursement for SE patients with less than a one week
LOS was approximately $7000, that for patients with
over one week stay was $32,907. A substantial
number of the SE patients (10%) had an LOS over
four weeks for an inpatient admission with a result-
ing reimbursement of over $60,000 per admission.
Table 4 provides a comparison of the relative
costs of an average inpatient admission for SE com-
pared with other common diagnoses (acute myo-
cardial infarction, intracranial hemorrhage, and
congestive heart failure). The ratio of costs for SE
patients ranged from 1.63 in patients with intracra-
nial hemorrhage to 1.94 compared with patients
admitted for congestive heart failure.Conclusion
SE is associated with significant direct health care
costs as reflected by reimbursement, both when
associated with other diseases and as an indepen-
dent etiology. The impact of this disease is sub-
stantial both because of the high cost and also
because of the number of cases, particularly in
the middle-aged and elderly population. In other
studies of SE, the elderly population was found to
have the highest incidence of SE and an associated
mortality of 34%.11,17 The anticipated rapid expan-
sion of the elderly population over the next two
decades will only increase the economic impact of
this disease on the Medicare system, reinforcing the
necessity of further evaluating the burden of SE
from a health policy and reimbursement perspec-
tive.
Although the estimate reported in the current
study reflects only the acute episode related to the
hospital admission for status, it provides a measure
of the potential economic impact of this disease.
Based on an epidemiologic study of SE by DeLorenzo
et al.10, suggesting that there are approximately
200,000 episodes of SE per year in the U.S. popula-
tion, the direct costs to the health care system for
SE admissions may be as high as $4 billion per year.
This estimate is based on inpatient reimbursement
from one hospital system, but it is similar in mag-
nitude to the estimate by Murray and others of $1.3
billion per year for refractory epilepsy.3 The esti-
mated median direct health care costs based on
reimbursement of an episode of SE from this ana-
lysis were $8417 and were substantially higher than
the total average annual costs in the initial year
after diagnosis of $3157 for all epilepsy reported by
Begley.8 The costs from the two studies are not
directly comparable because of differences in
health care settings and methods of estimation,
nevertheless, the results suggest that status repre-
sents a portion of the epilepsy population with a
significantly greater component of direct health
care costs.4,9
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costs of providing health care across different
health care settings. However, comparing the ratio
of costs within the same health care system for SE
and other diagnoses provides a relative measure of
the magnitude of health care costs associated with
an episode of SE. In this study, an inpatient admis-
sion for status was associated with a 60—90% greater
direct cost than that for admissions with other
diagnoses.
Further study is needed to evaluate the addi-
tional direct costs of SE for physician visits, out-
patient care, laboratory tests and pharmacy
charges as well as emergency department care,
and to evaluate in more detail the impact of comor-
bid conditions on the LOS and costs for SE. Further,
reimbursement is a measure of the economic bur-
den to the health care system, but may not accu-
rately reflect the costs to the entity providing care,
and does not include the direct and indirect costs to
the patient and his family. A study providing infor-
mation on the longitudinal health care costs of SE
that includes inpatient and subsequent outpatient
care as well as costs of readmission would provide
important information on the total costs of seque-
lae of this condition. As new treatments for SE are
developed, this type of analysis would permit an
assessment of their effectiveness from an economic
perspective. Given the significant morbidity and
cost burden associated with this diagnosis, further
efforts towards refining the costs of this disease are
indicated. The results of a more complete analysis
may be useful in establishing and refining reimbur-
sement rates or in defining this disease as an inde-
pendent diagnostic category for reimbursement.Acknowledgement
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